ClinicalTrials.gg
TerminatedNCT00605384Updated Nov 23, 2010Results posted

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

A Phase 3 interventional study of Entecavir + Tenofovir and Adefovir + continuing Lamivudine in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Terminated at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-23.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Objectives Have Changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
59th of 61
4 · median 109
Started
2008
with 7 others
Phase 3
13 of 64
none open now
Registered
12th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 59th largest by enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2008, is one of 13 in phase 3, and was the 12th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to find out whether a combination of entecavir (ETV) plus tenofovir (TNF) works better against Hepatitis B virus than adefovir (ADV) added to continuing lamivudine (LVD) therapy in patients whose Hepatitis B virus (HBV) is resistant against lamivudine. The safety of this treatment will also be studied.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic infection
  • History of lamivudine (LVD) treatment, and lamivudine resistance (LVDr), receiving LVD at screening visit
  • Compensated liver function
  • HBV DNA ≥ 172,000 IU/mL
  • Hepatitis B e-antigen (HBeAg)-positive or HBeAg-negative

Exclusion criteria

Exclusion Criteria:

  • Evidence of decompensated cirrhosis
  • Coinfection with (HIV), virus (HCV), or hepatitis D virus (HDV)
  • Recent history of pancreatitis
  • Serum alpha fetoprotein > 100 ng/mL
  • Except lamivudine, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    1

    Drug: Entecavir + Tenofovir

  • Experimental
    2

    Drug: Adefovir + continuing Lamivudine

Interventions

  • DrugEntecavir + Tenofovir

    Drug pages: Entecavir · Tenofovir

    Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks

    Also known as: Baraclude

  • DrugAdefovir + continuing Lamivudine

    Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved an Hepatitis B Virus DNA (HBV DNA) Level < 50 IU/mL at Week 48

    using the Roche COBAS® TaqMan HBV Test for use with the High Pure System (HPS) assay, by Polymerase Chain Reaction (PCR); HBV DNA \< 50 IU/mL = approximately 300 copies/mL

    Time frame: Week 48

Secondary outcomes

  1. Number of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 96

    by PCR, using the Roche COBAS®TaqMan - HPS assay; HBV DNA \< 50 IU/mL = approximately 300 copies/mL.

    Time frame: Week 96

  2. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.

    Time frame: Day 1 through end of treatment (Week 100 +/- 5 days)

  3. Number of Participants Who Achieved HBV DNA < the Lower Limit of Detection (LLD) at Weeks 48 and 96

    by PCR, using the Roche for the Roche COBAS® TaqMan - HPS assay. LLD = 4.8 IU/mL (approximately 28 copies/mL)

    Time frame: Week 48, Week 96

  4. HBV DNA Values at Weeks 48 and 96

    Number of Participants with HBV DNA \<LLD (4.8); LLD to \<50; 50 to \<172; 172 to \<1,720; 1,720 to \<17,200; and ≥17,200 IU/mL (\<LLD (28); 28 to \<300; 300 to \<1,000; 1,000 to \<10,000; 10,000 to \<100,000; and ≥100,000 copies/mL by PCR, using the Roche COBAS®TaqMan - HPS assay

    Time frame: Weeks 48, Week 96

  5. Mean log10 Reduction From Baseline in HBV DNA at Weeks 48 and 96

    by PCR, using the Roche COBAS®TaqMan - HPS assay

    Time frame: Week 48, Week 96

  6. Number of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieved ALT Normalization (≤ 1 x ULN) at Weeks 48 and 96

    Time frame: Week 48, Week 96

  7. Number of Participants Who Were Hepatitis B E-antigen (HBeAg)-Positive at Baseline With Loss of HBeAg at Weeks 48 and 96

    HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication.

    Time frame: Baseline, Week 48, Week 96

  8. Number of Participants Who Were HBeAg-positive at Baseline With HBe Seroconversion at Weeks 48 and 96

    HBe seroconversion = HBeAg loss and presence of hepatitis B e-antibody (HBeAb)

    Time frame: Baseline, Week 48, Week 96

  9. Number of Participants With Hepatitis-B-Virus Surface Antigen of the (HBsAg) Loss at Weeks 48 and 96

    Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection

    Time frame: Week 48, Week 96

  10. Number of Participants With HBs Seroconversion (HBsAg Loss and Presence of HBsAb) at Weeks 48 and 96

    Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAb = HBsAg antibodies. HBs Seroconversion = HBsAg loss and presence of HBseAb

    Time frame: Week 48, Week 96

  11. Number of Participants With Genotypic Resistance Based on Analysis of Samples From Participants With HBV DNA ≥ 50 IU/mL at Weeks 48 and 96

    HBV DNA ≥ 50 IU/mL = approximately 300 copies/mL

    Time frame: Week 48, Week 96

07

Results

Posted Aug 10, 2010
Limitations and caveats
Following review of business priorities, BMS decided to terminate this study at an early stage. This was a strategic decision, not based on clinical or safety concerns. Due to limited data, no conclusions on safety and efficacy can be made.

Participant flow

A total of 84 subjects were to be treated with entecavir (ETV) plus tenofovir (TNF) or adefovir (ADV) added to continuing lamivudine (LVD).

Participant flow — Overall Study
MilestoneEntecavir + TenofovirAdefovir + Continuing Lamivudine
Started11
Completed00
Not completed11

Outcome measures

PrimaryNumber of Participants Who Achieved an Hepatitis B Virus DNA (HBV DNA) Level < 50 IU/mL at Week 48

using the Roche COBAS® TaqMan HBV Test for use with the High Pure System (HPS) assay, by Polymerase Chain Reaction (PCR); HBV DNA \< 50 IU/mL = approximately 300 copies/mL

Time frame:
Week 48
Reported as:
Number · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 96

by PCR, using the Roche COBAS®TaqMan - HPS assay; HBV DNA \< 50 IU/mL = approximately 300 copies/mL.

Time frame:
Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.

Time frame:
Day 1 through end of treatment (Week 100 +/- 5 days)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities
participantsEntecavir + TenofovirAdefovir + Continuing Lamivudine
AEs11
SAEs00
Deaths00
Discontinuations due to AEs00
Discontinuations due to Laboratory Abnormalities00
SecondaryNumber of Participants Who Achieved HBV DNA < the Lower Limit of Detection (LLD) at Weeks 48 and 96

by PCR, using the Roche for the Roche COBAS® TaqMan - HPS assay. LLD = 4.8 IU/mL (approximately 28 copies/mL)

Time frame:
Week 48, Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryHBV DNA Values at Weeks 48 and 96

Number of Participants with HBV DNA \<LLD (4.8); LLD to \<50; 50 to \<172; 172 to \<1,720; 1,720 to \<17,200; and ≥17,200 IU/mL (\<LLD (28); 28 to \<300; 300 to \<1,000; 1,000 to \<10,000; 10,000 to \<100,000; and ≥100,000 copies/mL by PCR, using the Roche COBAS®TaqMan - HPS assay

Time frame:
Weeks 48, Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryMean log10 Reduction From Baseline in HBV DNA at Weeks 48 and 96

by PCR, using the Roche COBAS®TaqMan - HPS assay

Time frame:
Week 48, Week 96
Reported as:
Mean · log10

No measurements were reported for this outcome.

SecondaryNumber of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieved ALT Normalization (≤ 1 x ULN) at Weeks 48 and 96
Time frame:
Week 48, Week 96
Reported as:
Number · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Were Hepatitis B E-antigen (HBeAg)-Positive at Baseline With Loss of HBeAg at Weeks 48 and 96

HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Number · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Were HBeAg-positive at Baseline With HBe Seroconversion at Weeks 48 and 96

HBe seroconversion = HBeAg loss and presence of hepatitis B e-antibody (HBeAb)

Time frame:
Baseline, Week 48, Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Hepatitis-B-Virus Surface Antigen of the (HBsAg) Loss at Weeks 48 and 96

Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection

Time frame:
Week 48, Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With HBs Seroconversion (HBsAg Loss and Presence of HBsAb) at Weeks 48 and 96

Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAb = HBsAg antibodies. HBs Seroconversion = HBsAg loss and presence of HBseAb

Time frame:
Week 48, Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Genotypic Resistance Based on Analysis of Samples From Participants With HBV DNA ≥ 50 IU/mL at Weeks 48 and 96

HBV DNA ≥ 50 IU/mL = approximately 300 copies/mL

Time frame:
Week 48, Week 96
Reported as:
Number · participants

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entecavir + Tenofovir—0/1 (0%)1/1 (100%)
Adefovir + Continuing Lamivudine—0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventEntecavir + TenofovirAdefovir + Continuing Lamivudine
HyperchlorhydriaGastrointestinal disorders1/10/1
HepatitisHepatobiliary disorders0/11/1
FatigueGeneral disorders0/11/1

Baseline characteristics

Age, Customized
Age, Customized(participants)Entecavir + TenofovirAdefovir + Continuing LamivudineTotal
Between 18 and 65 years011
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir + TenofovirAdefovir + Continuing LamivudineTotal
Female101
Male011
08

Study locations

29 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Kaiser Permanente Medical Center
    San Francisco, California 94118, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Local Institution
    New York, New York 10025, United States
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Berlin, 13353, Germany
  • Local Institution
    Bonn, 53105, Germany
  • Local Institution
    Duesseldorf, 40237, Germany
  • Local Institution
    Mainz, 55131, Germany
  • Local Institution
    Messina, 98124, Italy
  • Local Institution
    Modena, 41100, Italy
  • Local Institution
    Naples, 80135, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    San Giovanni Rotondo, 71013, Italy
  • Local Institution
    Chorzow, 41-500, Poland
  • Local Institution
    Krakow, 31-531, Poland
  • Local Institution
    Lublin, 20-089, Poland
  • Local Institution
    Ankara, 06010, Turkey
  • Local Institution
    Ankara, 06620, Turkey
  • Local Institution
    Istanbul, 34093, Turkey
  • Local Institution
    Istanbul, 34098, Turkey
  • Local Institution
    Istanbul, 34360, Turkey
  • Local Institution
    Istanbul, 34460, Turkey
  • Local Institution
    Istanbul, 34722, Turkey
  • Local Institution
    Izmir, 35100, Turkey
  • Local Institution
    Kocaeli, 41380, Turkey
  • Local Institution
    Sihhiye Ankara, 06100, Turkey
  • Local Institution
    Trabzon, 61080, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2008
First posted
Jan 31, 2008
Start
Aug 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Aug 10, 2010
Last update
Nov 23, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00605384
First posted
Jan 31, 2008
Start date
Aug 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Aug 10, 2010
Last update
Nov 23, 2010

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Tenofovir

Start the discussion